Gastric Antisecretory Drug Market
Gastric Antisecretory Drug Market Size, Share, and Trends Analysis Report, By Type (H2-receptor Antagonists, Gastric Proton Pump Inhibitors, and Others), By Application (Dyspepsia, Peptic Ulcer, Gastroesophageal Reflux, and Others), By End-User (Hospitals, Clinics, and Others), Forecast Period (2022 to 2028)
Gastric antisecretory drug market is anticipated to grow at a CAGR of 3.8% during the forecast period. Antisecretory drugs assist in reducing the normal rate of secretion of a body fluid that reduces acid secretion into the stomach. Such drugs include antimuscarinic drugs, H2-receptor antagonists and proton-pump inhibitors. The surging prevalence of gastrointestinal disorders such as dyspepsia, peptic ulcer, and gastroesophageal reflux is the prominent factor that has boosted the demand for gastric antisecretory drugs. In the US, peptic ulcer disease affects approximately 4.6 million people annually, with an estimated 10% of the US population having evidence of a duodenal ulcer at some time, according to Harvard Health. Apart from these, the growing prevalence of stress-induced ulcers due to changing lifestyles and diet, increasing smoking rate, and progressive population of geriatrics is anticipated to promote the growth of the global gastric antisecretory drug market. Moreover, significant partnerships, collaborations and new product development by the market players are likely to generate new growth opportunities for the market.
For instance, in July 2021, Shandong Luoxin Pharmaceutical Group Stock Co., a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. signed a cooperation agreement with South Korea-based HK Inno. N Corp. for the development, manufacture, and commercialization of Tegoprazan injections in China. Tegoprazan injections have mainly been developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and upper gastrointestinal bleeding as well as for the prevention of stress gastric mucosa injury. Similar, in July 2020, Cadila Pharmaceuticals Ltd. launched Esomeprazole tablets for the treatment of Hyperacidity & Drug Induced Gastritis under the brand name Esiloc. Esomeprazole which is a proton pump inhibitor (PPI), acts on the luminal surface of gastric parietal cells, resulting in inhibition of acid secretion. Esomeprazole provides higher rates of healing of erosive GERD and sustained resolution of heartburn in patients.
Segmental Outlook
The global gastric antisecretory drug market is segmented based on type, application, and end-user. Based on type, the market is segmented into H2-receptor antagonists, gastric proton pump inhibitors, and others. Among these, the H2-receptor antagonists' segment is likely to hold a considerable share of the growth of the global antisecretory drug market. The high demand for H2-receptor antagonists in the treatment of acid-peptic disease including duodenal and gastric ulcers, inflamed stomach gastroesophageal reflux disease, common heartburn, and peptic ulcers is the major factor driving the segment growth. High prevalence and increasing incidence of duodenal and gastric ulcers, inflamed stomach gastroesophageal reflux disease, and peptic ulcer disease in developed economies is the major factor boosting the segment growth. Based on application, the market is segmented into dyspepsia, peptic ulcer, gastroesophageal reflux, and others. Among these, the gastroesophageal reflux segment is expected to gain a high share of the market owing to the high prevalence of GERD in major economies that have led to the development of novel therapeutics drugs such as a gastric antisecretory drugs. Based on end-user, the market is segmented into hospitals, clinics, and others.
Regional Outlook
Geographically, the global gastric antisecretory drug market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). The Asia-Pacific region is likely to be the fastest growing region in the global antisecretory drug market during the forecast period. The regional growth is driven by the increasing prevalence of different gastrointestinal diseases and disorders in the region’s major economies, the rising geriatric population, and increasing investment in R&D by pharmaceutical companies. Additionally, changing lifestyles and increasing awareness about the availability of the treatment are the other factors fueling the regional market growth.
Global Gastric Antisecretory Drug Market Growth, By Region 2022-2028
North America Region Holds the Largest Share in Gastric Antisecretory Drug Market
Geographically, the North America region held the largest share in the market. The region is estimated to contribute the highest share to the growth of the market. The government initiatives educating the people about the various diseases and their treatment availability is the prominent factor driving the market growth. Developed health care infrastructure and large patient population along with increasing technological development will further lead the positive growth in the market. Besides, the presence of prominent players such as AstraZeneca plc, Bayer AG, Pfizer, Inc., Sanofi-Aventis US LLC, and new product launches by them driving the regional market growth.
Market Players Outlook
The major market players in the global gastric antisecretory drug market include Pfizer Inc., Sanofi-Aventis US LLC, and Takeda Pharmaceutical Co. Ltd., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global gastric antisecretory drug market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Recovery Scenario of Global Gastric Antisecretory Drug Industry
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Gastric Antisecretory Drug Market by Type
4.1.1. H2-receptor Antagonists
4.1.2. Gastric Proton Pump Inhibitors
4.1.3. Others
4.2. Global Gastric Antisecretory Drug Market by Application
4.2.1. Dyspepsia
4.2.2. Peptic Ulcer
4.2.3. Gastroesophageal Reflux
4.2.4. Others
4.3. Global Gastric Antisecretory Drug Market by End-User
4.3.1. Hospital
4.3.2. Clinic
4.3.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
5.4.1. Latin America
5.4.2. Middle East & Africa
6. Company Profiles
6.1. ALTANA Group
6.2. AstraZeneca plc
6.3. Bayer AG
6.4. Cadila Pharmaceuticals
6.5. Cheplapharm Arzneimittel GmbH
6.6. Cipla Inc.
6.7. Eisai Co., Ltd
6.8. Luoxin Group
6.9. Pfizer, Inc.
6.10. Novartis International AG
6.11. SANIS Health Inc.
6.12. Sanofi-Aventis U.S. LLC
6.13. Shandong Luoxin Pharmaceutical Group Stock co., ltd
6.14. Takeda Pharmaceutical Co. Ltd.
1. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL H2-RECEPTOR ANTAGONISTS IN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL GASTRIC PROTON PUMP INHIBITORS IN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL OTHER GASTRIC ANTISECRETORY DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
6. GLOBAL GASTRIC ANTISECRETORY DRUG IN DYSPEPSIA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL GASTRIC ANTISECRETORY DRUG IN PEPTIC ULCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL GASTRIC ANTISECRETORY DRUG IN GASTROESOPHAGEAL REFLUX MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL GASTRIC ANTISECRETORY DRUG IN OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
11. GLOBAL GASTRIC ANTISECRETORY DRUG FOR HOSPITAL MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL GASTRIC ANTISECRETORY DRUG FOR CLINIC MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL GASTRIC ANTISECRETORY DRUG FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
16. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
17. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
18. NORTH AMERICAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
19. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
22. EUROPEAN GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
23. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
24. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
27. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
28. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
29. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
30. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET RESEARCH AND ANALYSIS BY END-USER, 2021-2028 ($ MILLION)
1. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY TYPE, 2021 VS 2028 (%)
2. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
3. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY END-USER, 2021 VS 2028 (%)
4. GLOBAL GASTRIC ANTISECRETORY DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
5. GLOBAL H2-RECEPTOR ANTAGONISTS IN GASTRIC ANTISECRETORY DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
6. GLOBAL GASTRIC PROTON PUMP INHIBITORS IN GASTRIC ANTISECRETORY DRUG MARKET SHARE BY REGION, 2021 VS 2028 (%)
7. GLOBAL OTHER GASTRIC ANTISECRETORY DRUGS MARKET SHARE BY REGION, 2021 VS 2028 (%)
8. GLOBAL GASTRIC ANTISECRETORY DRUG IN DYSPEPSIA MARKET SHARE BY REGION, 2021 VS 2028 (%)
9. GLOBAL GASTRIC ANTISECRETORY DRUG IN PEPTIC ULCER MARKET SHARE BY REGION, 2021 VS 2028 (%)
10. GLOBAL GASTRIC ANTISECRETORY DRUG IN GASTROESOPHAGEAL REFLUX MARKET SHARE BY REGION, 2021 VS 2028 (%)
11. GLOBAL GASTRIC ANTISECRETORY DRUG IN OTHER APPLICATIONS MARKET SHARE BY REGION, 2021 VS 2028 (%)
12. GLOBAL GASTRIC ANTISECRETORY DRUG FOR HOSPITAL MARKET SHARE BY REGION, 2021 VS 2028 (%)
13. GLOBAL GASTRIC ANTISECRETORY DRUG FOR CLINIC MARKET SHARE BY REGION, 2021 VS 2028 (%)
14. GLOBAL GASTRIC ANTISECRETORY DRUG FOR OTHER END-USERS MARKET SHARE BY REGION, 2021 VS 2028 (%)
15. US GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. CANADA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. UK GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. FRANCE GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. GERMANY GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. ITALY GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. SPAIN GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF EUROPE GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. INDIA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. CHINA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. JAPAN GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
26. SOUTH KOREA GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF ASIA-PACIFIC GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
28. REST OF THE WORLD GASTRIC ANTISECRETORY DRUG MARKET SIZE, 2021-2028 ($ MILLION)
